Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > My previous bullish PLX call & my new bullish call on TVL

<< Previous

Bullboard Posts

Next >>

Comment by mike49on Apr 07, 2019 12:48pm

76 Views

Post# 29593673

RE:RE:RE:RE:My previous bullish PLX call & my new bullish call on TVL

Ya, I'm not wearing a tin hat. Just found it odd that the jv partner would even mention going alone.
I'm still curious as to what Mitchel's game is here, even if his story is "undervalued junior". Wonder if he has his fingers in whitebark.
that's a rabbit hole for another day
Cheers

<< Previous

Bullboard Posts

Next >>

Crypto and blockchain stock ends year with a profit